On Air Now

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 1360 AM Northeast, WI 97.5 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
40° Feels Like: 31°
Wind: SSW 18 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Rain/Wind 36°

Tomorrow

AM Rain/Snow Showers 46°

Fri Night

Partly Cloudy 27°

Alerts

GSK says melanoma combination meets main goal

LONDON (Reuters) - GlaxoSmithKline said on Friday the first of its phase three studies into the combination of Tafinlar and Mekinist to treat melanoma, the deadliest form of skin cancer, had met its main goal.

The results, along with further data expected from the study, will increase the body of evidence on the safety and efficiacy of the combination, the British company said.

The combined use of Tafinlar, also known as dabrafenib, and Mekinist, or trametinib, was given the green light from the Food and Drug Administration (FDA) in the U.S. earlier this month.

(Reporting by Kate Holton, Editing by Paul Sandle)

Comments